Clifford Saffron
Directeur Général chez OPTIMUS HEALTHCARE SERVICES, INC.
Profil
Clifford R.
Saffron is currently the President, CEO, COO & General Counsel at Optimus Healthcare Services, Inc. He previously served as the Chief Executive Officer at Animal Surgical Center of Michigan LLC from 2020 to 2021.
Prior to that, he was the Director-Business Development at Kps Life Sciences from 2018 to 2020.
From 2002 to 2005, he worked as the General Counsel & Senior Vice President at ImClone LLC.
Mr. Saffron also held the position of President at Hoffman Technologies, Inc. from 2018 to 2020.
He served as the Deputy General Counsel & Senior Vice President at ICN Pharmaceuticals, Inc. from 1994 to 2001.
Additionally, he was a Member-Management Board at Yamo Pharmaceuticals LLC from 2018 to 2020.
Postes actifs de Clifford Saffron
| Sociétés | Poste | Début |
|---|---|---|
| OPTIMUS HEALTHCARE SERVICES, INC. | Directeur Général | 27/07/2023 |
Anciens postes connus de Clifford Saffron
| Sociétés | Poste | Fin |
|---|---|---|
| Animal Surgical Center of Michigan LLC | Directeur Général | 01/03/2021 |
Hoffman Technologies, Inc.
 Hoffman Technologies, Inc. Information Technology ServicesTechnology Services Hoffman Technologies, Inc. provides information technology services. It offers technology hardware, software, and services resale. The firm also offers technology products, technology services, office supplies, janitorial supplies, tactical supplies, industrial supplies, and various other consumer and consumable products. It also offers services to distributors, wholesalers, retailers and manufacturers. The company was founded by Gary C. Hoffman and Kevin Hoffman in 1997 and is headquartered in Rocklin, CA. | President | 01/03/2020 |
Yamo Pharmaceuticals LLC
 Yamo Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Yamo Pharmaceuticals LLC is a clinical stage pharmaceutical company that was founded in 2015. Yamo Pharmaceuticals is a privately held company and is based in New York, NY. The company's focus is on developing L1-79, a novel therapy that has the potential to improve the core symptoms of ASD. The CEO of the company is Charles J. Bramlage. | Corporate Officer/Principal | 01/03/2020 |
| Kps Life Sciences | Corporate Officer/Principal | 01/03/2020 |
ImClone LLC
 ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | Conseiller Juridique Général | 01/02/2005 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| OPTIMUS HEALTHCARE SERVICES, INC. | Consumer Non-Durables |
| Entreprise privées | 6 |
|---|---|
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | Health Technology |
Hoffman Technologies, Inc.
Hoffman Technologies, Inc. Information Technology ServicesTechnology Services Hoffman Technologies, Inc. provides information technology services. It offers technology hardware, software, and services resale. The firm also offers technology products, technology services, office supplies, janitorial supplies, tactical supplies, industrial supplies, and various other consumer and consumable products. It also offers services to distributors, wholesalers, retailers and manufacturers. The company was founded by Gary C. Hoffman and Kevin Hoffman in 1997 and is headquartered in Rocklin, CA. | Technology Services |
| ICN Pharmaceuticals, Inc. /Old/ | Health Technology |
Yamo Pharmaceuticals LLC
Yamo Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Yamo Pharmaceuticals LLC is a clinical stage pharmaceutical company that was founded in 2015. Yamo Pharmaceuticals is a privately held company and is based in New York, NY. The company's focus is on developing L1-79, a novel therapy that has the potential to improve the core symptoms of ASD. The CEO of the company is Charles J. Bramlage. | Health Technology |
| Kps Life Sciences | |
| Animal Surgical Center of Michigan LLC |
